Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
ConditionCancer
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorAgenus Inc.
About this trial
This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.
Disqualifiers
None
Trial design
Treatments tested in this trial
Balstilimab
DrugAn anti-programmed death 1 (PD-1) monoclonal antibody.
Zalifrelimab
DrugAn anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov